The Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery
An Observational Study on the Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
80 participants
Jun 1, 2024
INTERVENTIONAL
Conditions
Summary
This study aims to compare the use of sugammadex (domestic) and neostigmine for antagonism after thoracic surgery, and observe the effect of sugammadex (domestic) on neuromuscular blockade antagonism after thoracic surgery, in order to provide a basis for optimizing the use of muscle relaxants and their antagonists during anesthesia.
Eligibility
Inclusion Criteria5
- Patients who undergo elective lung surgery under general anesthesia and require endotracheal intubation;
- Age>18 years old, gender not limited;
- American Society of Anesthesiologists ASA Level I-III;
- Use rocuronium bromide for neuromuscular blockade;
- The patient voluntarily participated in the trial.
Exclusion Criteria5
- The patient explicitly refused to participate in this trial;
- Family history of malignant hyperthermia, patients with allergies to sodium sulbactam, neostigmine ingredients and their excipients, and patients with allergies to drugs used during general anesthesia;
- Patients with tracheal malformations or suspected difficult airways, coagulation dysfunction, severe liver and kidney dysfunction, and severe lung disease;
- Patients who are not extubated and sent to the ward or ICU after surgery;
- The researchers believe that patients with any other unfavorable factors to participate in this trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The dose of Sugammadex Sodium 100 Mg in 1 mL is 2mg/kg
Neostigmine is 50 μg/kg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06334562